We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
+39.96%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$1.48B
AUM Growth
+$386M
Cap. Flow
+$89.6M
Cap. Flow %
6.06%
Top 10 Hldgs %
43.47%
Holding
92
New
20
Increased
28
Reduced
19
Closed
16

Top Buys

Rank Stock Value
1
ALHC icon
Alignment Healthcare
ALHC
+$17.8M
2
CYTK icon
Cytokinetics
CYTK
+$16.5M
3
VERA icon
Vera Therapeutics
VERA
+$12.7M
4
CNC icon
Centene
CNC
+$12.1M
5
ISRG icon
Intuitive Surgical
ISRG
+$12M

Top Sells

Rank Stock Value
1
MLYS icon
Mineralys Therapeutics
MLYS
+$26M
2
BSX icon
Boston Scientific
BSX
+$25.9M
3
DXCM icon
DexCom
DXCM
+$17.5M
4
GEHC icon
GE HealthCare
GEHC
+$14.8M
5
EHC icon
Encompass Health
EHC
+$14.3M

Sector Composition

Rank Sector Weight
1 Healthcare 92.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OSCR icon
51
Oscar Health
OSCR
$8.63B
$10.4M 0.7%
550,000
+450,000
+450% +$7.42M
DYN icon
52
Dyne Therapeutics
DYN
$4.99B
$10.1M 0.68%
+800,000
New +$9.12M
BHVN icon
53
Biohaven
BHVN
$2.19B
$9.76M 0.66%
650,000
+350,000
+117% +$5.09M
BEAM icon
54
Beam Therapeutics
BEAM
$2.77B
$9.71M 0.66%
400,000
-100,000
-20% -$1.99M
CRL icon
55
Charles River Laboratories
CRL
$13.5B
$9.39M 0.64%
60,000
-55,000
-48% -$8.74M
INSP icon
56
Inspire Medical Systems
INSP
$1.71B
$8.9M 0.6%
120,000
+50,000
+71% +$5.06M
IQV icon
57
IQVIA
IQV
$40.1B
$8.55M 0.58%
+45,000
New +$8.18M
LFST icon
58
Lifestance Health
LFST
$4.39B
$8.25M 0.56%
+1,500,000
New +$7.35M
GKOS icon
59
Glaukos
GKOS
$10.7B
$8.15M 0.55%
100,000
+50,000
+100% +$4.59M
ARWR icon
60
Arrowhead Research
ARWR
$12.6B
$7.76M 0.53%
+225,000
New +$4.95M
ACHC icon
61
Acadia Healthcare
ACHC
$2.9B
$7.43M 0.5%
300,000
-100,000
-25% -$2.23M
TERN
62
DELISTED
Terns Pharmaceuticals
TERN
$7.13M 0.48%
950,000
+250,000
+36% +$1.6M
SANA icon
63
Sana Biotechnology
SANA
$1.13B
$7.1M 0.48%
2,000,000
+500,000
+33% +$1.81M
HOLX
64
DELISTED
Hologic
HOLX
$6.75M 0.46%
100,000
-25,000
-20% -$1.66M
COO icon
65
Cooper Companies
COO
$15B
$6.51M 0.44%
95,000
+25,000
+36% +$1.77M
TARA icon
66
Protara Therapeutics
TARA
$220M
$6.09M 0.41%
1,400,000
– –
DNTH icon
67
Dianthus Therapeutics
DNTH
$6.07B
$5.9M 0.4%
+150,000
New +$3.83M
APLS
68
DELISTED
Apellis Pharmaceuticals
APLS
$5.66M 0.38%
+250,000
New +$5.83M
JNJ icon
69
Johnson & Johnson
JNJ
$626B
$5.56M 0.38%
+30,000
New +$5.14M
PHVS icon
70
Pharvaris
PHVS
$2.41B
$4.99M 0.34%
+200,000
New +$4.44M
ESPR
71
DELISTED
Esperion Therapeutics
ESPR
$3.98M 0.27%
+1,500,000
New +$2.9M
SRRK icon
72
Scholar Rock
SRRK
$6.34B
$3.72M 0.25%
100,000
– –
NRIX icon
73
Nurix Therapeutics
NRIX
$2.69B
$3.23M 0.22%
350,000
+40,000
+13% +$415K
ANRO icon
74
Alto Neuroscience
ANRO
$1.12B
$1.61M 0.11%
400,000
– –
LBRX
75
LB Pharmaceuticals
LBRX
$1.3B
$1.58M 0.11%
+100,000
New +$1.59M
1 2
3
4

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return
AG
Avala Global New York $2.08B AUM 87.66% 1-Year Est. Return

Integral Health Asset Management's Q3 2025 Portfolio in Review

As of Q3 2025, Integral Health Asset Management held 92 positions worth $1.48B, up 35% from $1.09B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Integral Health Asset Management deployed $89.6M of net new capital in Q3 2025, opening 20 new positions and adding to 28 existing holdings. Its largest new stake was Centene: 400,000 shares worth $14.3M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 98% a quarter earlier.

On the sell side, the largest reduction was Mineralys Therapeutics, an estimated $26M trimmed.

  • Integral Health Asset Management's largest Q3 2025 buy was Centene: 400,000 shares worth $14.3M.
  • Integral Health Asset Management added most to Alignment Healthcare in Q3 2025, an estimated $17.8M increase.
  • Integral Health Asset Management's biggest Q3 2025 reduction was Mineralys Therapeutics, cutting an estimated $26M.
  • Integral Health Asset Management fully exited DexCom in Q3 2025, selling an estimated $17.5M.
  • Integral Health Asset Management's ten largest holdings make up 43% of its $1.48B portfolio in Q3 2025.
  • Integral Health Asset Management opened 20 new positions and closed 16 in Q3 2025.
  • Integral Health Asset Management's portfolio value rose 35% quarter-over-quarter to $1.48B.

Based on Integral Health Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.